---

• Hohmann N, Schröder F, Moreira B, Teng H, Burhenne J, Bruckner T, Mueller S, Haefeli WE, Seitz HK. Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease. Gut 2022;71:842-844.
• Rohr BS, Foerster KI, Blank A, Burhenne J, Mahmoudi M, Haefeli WE, Mikus G. Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. Clin Pharmacokinet 2022;61:97-109.
• Stoll F, Blank A, Mikus G, Czock D, Foerster KI, Hermann S, Gümüs K, Muhareb A, Hummler S, Sauter M, Weiss J, Burhenne J, Haefeli WE. Effect of pantoprazole on the absorption of hydroxychloroquine - a randomized drug-drug interaction trial in healthy adults. Clin Pharmacol Drug Dev 2021;21:584.
• Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE. Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. Br J Clin Pharmacol 2019;85:2310-20.
• Blank A, Eidam A, Haag M, Hohmann N, Burhenne J, Schwab M, van de Graaf S, Meyer MR, Maurer HH, Meier K, Weiss J, Bruckner T, Alexandrov A, Urban S, Mikus G, Haefeli WE. The NTCP inhibitor Myrcludex B: Effects on bile acid disposition and tenofovir pharmacokinetics. Clin Pharmacol Ther 2018;103:341-8.
• Geist MJP, Egerer G, Mikus G, Blank A, Hohmann N, Heinz W, Carls A. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions. Basic Clin Pharmacol Toxicol 2019; 124: 56-61.
• Hohmann N, Kreuter R, Blank A, Weiss J, Burhenne J, Haefeli WE, Mikus G. Auto-inhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. Br J Clin Pharmacol 2017;83:1954-65.